| pubmed-article:7932562 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7932562 | lifeskim:mentions | umls-concept:C0034428 | lld:lifeskim |
| pubmed-article:7932562 | lifeskim:mentions | umls-concept:C1533693 | lld:lifeskim |
| pubmed-article:7932562 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:7932562 | lifeskim:mentions | umls-concept:C0038477 | lld:lifeskim |
| pubmed-article:7932562 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:7932562 | pubmed:issue | 20 | lld:pubmed |
| pubmed-article:7932562 | pubmed:dateCreated | 1994-11-3 | lld:pubmed |
| pubmed-article:7932562 | pubmed:abstractText | A series of novel chiral 7-(7-amino-5-azaspiro[2.4]heptan-4-yl)-8-chloro-1-(2-fluo rocyclopropyl)- quinolones were synthesized as a continuation of a research project of 1-(2-fluorocyclopropyl)-quinolones by considering stereochemical and physicochemical properties of the molecule. Absolute configurations of the 1-(cis-2-fluorocyclopropyl) moiety and the 7-(7-amino-5-azaspiro-[2.4]heptan-5-yl) moiety were determined by X-ray crystallographic analysis. Stereochemical structure-activity relationship studies indicated that 1-[(1R,2S)-2-fluorocyclopropyl] and 7-[(7S)-amino-5-azaspiro[2.4]heptan-5-yl] derivatives are more potent against Gram-positive and Gram-negative bacteria than the other stereoisomers and 7-[(7S)-7-amino-5-azaspiro[2.4]-heptan-5-yl]-8-chloro-1-[(1R ,2S)-2- fluorocyclopropyl]quinolone (33) is the most potent of all stereoisomers. Pharmacokinetic profiles and physicochemical properties of the selected compounds were also examined, and it was found that 33 (DU-6859a) possesses moderate lipophilicity and good pharmacokinetic profiles. | lld:pubmed |
| pubmed-article:7932562 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7932562 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7932562 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7932562 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7932562 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7932562 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7932562 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7932562 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7932562 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7932562 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:7932562 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:7932562 | pubmed:author | pubmed-author:SatoKK | lld:pubmed |
| pubmed-article:7932562 | pubmed:author | pubmed-author:KimuraYY | lld:pubmed |
| pubmed-article:7932562 | pubmed:author | pubmed-author:HayakawaII | lld:pubmed |
| pubmed-article:7932562 | pubmed:author | pubmed-author:KawakamiKK | lld:pubmed |
| pubmed-article:7932562 | pubmed:author | pubmed-author:AtarashiSS | lld:pubmed |
| pubmed-article:7932562 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7932562 | pubmed:day | 30 | lld:pubmed |
| pubmed-article:7932562 | pubmed:volume | 37 | lld:pubmed |
| pubmed-article:7932562 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7932562 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7932562 | pubmed:pagination | 3344-52 | lld:pubmed |
| pubmed-article:7932562 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:meshHeading | pubmed-meshheading:7932562-... | lld:pubmed |
| pubmed-article:7932562 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7932562 | pubmed:articleTitle | (Fluorocyclopropyl)quinolones. 2. Synthesis and Stereochemical structure-activity relationships of chiral 7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-fluorocyclopropyl)quinolone antibacterial agents. | lld:pubmed |
| pubmed-article:7932562 | pubmed:affiliation | Exploratory Research Laboratories I, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan. | lld:pubmed |
| pubmed-article:7932562 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7932562 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:7932562 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7932562 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7932562 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7932562 | lld:pubmed |
